Melinda Day

Melinda Day has a diverse and extensive work experience in the field of biology and pharmaceuticals. Melinda is currently working as the Director of Translational Research and Operations at Editas Medicine since April 2023. Prior to this, they worked as an Associate Director of Translational Clinical Development at Kronos Bio, Inc. from October 2020 to March 2023.

Before joining Kronos Bio, Inc., Melinda served as an Associate Director of Biology at Cyteir Therapeutics from March 2019 to October 2020. In this role, they managed a team of researchers, handled collaborations with CROs and academic institutions, and provided scientific direction to the company. Melinda also held the position of Principal Scientist and Head of Discovery Biology at Cyteir Therapeutics from June 2017 to October 2020, where they managed CROs and scientific staff, conducted assays to uncover the mechanism of action of drug compounds, and explored new drug targets and indications.

Prior to their tenure at Cyteir Therapeutics, Melinda worked as a Senior Scientist at Roche Tissue Diagnostics (Ventana Medical Systems) from September 2015 to January 2017. In this role, they contributed to driving innovation in oncology diagnostics, identified research areas aligned with business interests, and established collaborations across different Roche business units.

Melinda's early career includes roles as a Postdoctoral Researcher at the University of Illinois (2013-2015) and the University of Illinois at Urbana-Champaign (2012-2013). During this time, they conducted research on genomic stability, gene transcription, and the neuroprotective effects of estrogen. Melinda gained expertise in various techniques such as yeast genetics, western blots, PCR, fluorescent microscopy, DNAseq, and immunohistochemistry.

Before their postdoctoral research positions, Melinda worked as a Graduate Student Research Assistant at the University of Michigan Ann Arbor from September 2007 to August 2012. In this role, they conducted research on autophagy, using techniques such as western blots, fluorescent microscopy, ChIP, and mammalian cell culture.

Melinda's work experience also includes an undergraduate internship at the University of South Carolina from May 2004 to May 2007. During this internship, they worked on studying post-translational modifications of Cox2 in relation to colon cancer, performing various techniques such as mammalian cell culture, western blots, and RT-PCR.

Lastly, Melinda had a summer internship at The University of Arizona in 2003, where they gained experience in material science engineering lab work.

Overall, Melinda Day has a strong background in biology and pharmaceutical research, with expertise in translational research, scientific management, and collaboration. Their experience spans both industry and academic settings, and they have a broad range of technical skills.

Melinda Day earned their Bachelor of Science degree in Biology from the University of South Carolina between 2003 and 2007. Melinda then pursued a PhD in Molecular and Cellular Biology at the University of Michigan Ann Arbor from 2007 to 2012.